Similarly, the CAPItello‐291 trial evaluated the efficacy of fulvestrant, with or without capivasertib, in HR‐positive, HER2‐negative breast cancer patients who had altered AKT pathways (nearly 75% were PIK3CA‐mutant). Here, AKT1 is linked to breast cancer.